1. Home
  2. NWG vs ARGX Comparison

NWG vs ARGX Comparison

Compare NWG & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NatWest Group plc (each representing two (2))

NWG

NatWest Group plc (each representing two (2))

N/A

Current Price

$14.87

Market Cap

67.6B

Sector

Finance

ML Signal

N/A

Logo argenx SE

ARGX

argenx SE

N/A

Current Price

$928.86

Market Cap

55.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NWG
ARGX
Founded
1727
2008
Country
United Kingdom
Netherlands
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.6B
55.1B
IPO Year
2011
2017

Fundamental Metrics

Financial Performance
Metric
NWG
ARGX
Price
$14.87
$928.86
Analyst Decision
Buy
Buy
Analyst Count
4
25
Target Price
$21.15
★ $1,150.61
AVG Volume (30 Days)
★ 5.0M
343.8K
Earning Date
10-30-2026
10-22-2026
Dividend Yield
★ 6.02%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$8.50
$53.06
Revenue Next Year
$7.08
$23.03
P/E Ratio
★ $18.92
$33.69
Revenue Growth
N/A
N/A
52 Week Low
$13.76
$661.85
52 Week High
$19.42
$1,072.75

Technical Indicators

Market Signals
Indicator
NWG
ARGX
Relative Strength Index (RSI) 32.73 51.26
Support Level $14.82 $836.30
Resistance Level $16.10 $941.15
Average True Range (ATR) 0.32 25.62
MACD -0.04 0.50
Stochastic Oscillator 2.22 50.08

Price Performance

Historical Comparison
NWG
ARGX

About NWG NatWest Group plc (each representing two (2))

NatWest Group derives around 90% of its total income from the United Kingdom. The bank operates a retail, commercial, and private bank in the UK, offering clients lending and payment services as well as asset management services.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: